Type 2 Diabetes Mellitus Clinical Trial
Official title:
Effectiveness of a Structured Group-Based Intervention "Know Your Medicine - Take It For Health" (KYM-TIFH) in Improving Medication Adherence Among Malay Patients With Underlying Type 2 Diabetes Mellitus in the Sarawak State of Malaysia: A Randomized Controlled Trial
Poor medication adherence (MA) among Type 2 Diabetes Mellitus (T2DM) patients had found to be
gnarly and devastating (Krass et al 2015; Sharma et al 2014). It was estimated that more than
half of the patients failed to achieve recommended glycaemic goals due to nonadherence
(García-Pérez 2013; World Health Organization 2003). Furthermore, greater adherence rate was
significantly associated with better glycemic control, fewer hospital visits and admissions,
and lower medical costs. On the other hand, lower adherence rate was significantly associated
with poor medication tolerance, the frequency of medication intake (> 2 times a day), having
concomitant depression and negative belief about the medications. Consequently, patients who
poorly adhere to medications would take more medications due to the poor glycemic control and
development of micro- and macrovascular complications (American Diabetes Association 2013).
Such condition would further worsen their adherence due to more complex medications and a
greater chance of experiencing drug-related side effects (García-Pérez 2013). This inevitably
increases the economic burden and wastage to the healthcare system (Meng et al 2017). Hence
breaking the vicious cycle is an urgent call to all stakeholders.
Notably, Ministry of Health Malaysia (MOH) had initiated several interventions in curbing the
MA problems at national level. One of those which has been perpetuated and led by pharmacists
is "Know Your Medicine" (KYM) Campaign since 2007. The national KYM campaign aims to promote
the quality use of medicines through mass communication and group-based approach. The
messages conveyed include information on their medication management such as why, how and
when to take medicines, reporting adverse drug events, awareness on the rational use of
medicines and medications that need special precautions. In specific, assuring and improving
medication adherence among patients is one of the important components of the campaign (PSD
2008).
In term of improving medication adherence among Malay T2DM patients, a structured group-based
intervention (SGBI) called "Know Your Medicine - Take It For Health" with abbreviation
KYM-TIGF, was created by the researchers of this study who work at Sarawak Pharmaceutical
Services Division in 2016 under the KYM campaign. The KYM-TIGF is a theoretical based,
patient empowerment, culturally appropriate and a combination of psychosocial, educational
and behavioral intervention. It is a one-off SGBI that aims to improve the medication
adherence through the message specially designed with a cross-theoretical framework as
recommended by Slater (1999). The model to measure the effectiveness of the SGBI is an
integrated model with Theory of Planned Behaviour (Ajzen 1991) as main theory and
Information-Motivation-Behavioural Skills Model (Fisher et al. 2006) as supporting theory.
The primary outcome of this study is the HbA1c. The secondary outcomes of this study are the
medication adherence level as well as the psychosocial variables of the integrated model
which include attitude to medication adhere, the subjective norm to medication adherence,
perceived behavioral control towards medication adherence, adherence information, adherence
skill and intention to adhere.
A current systematic review by Odgers-Jewell et al (2017) revealed that little had been done
to investigate the effectiveness of group based education in improving medication adherence
among T2DM patients. This concur with the comprehensive review on interventions to improve
medication adherence by Conn & Ruppar (2017), as the researchers conclude that there is an
urgent need in evaluating the interventions to improve medication adherence that employs
group-based approach.
The evidence on the effectiveness of the KYM-TIFH in promoting medication adherence among
T2DM patients remain lacking. Furthermore, the current measurement on the effectiveness of
the campaign is the increment of the awareness level of public towards proper use of
medicines (PSD 2013) without measuring the impact of the campaign on actual behavior change.
Besides aforementioned, Malay ethnic was found to be the main contributor to the prevalence
of poor MA (PSD 2013) due to forgetfulness (75.3%) and reluctant to take prescribed
medications (43.8%). Facing the high prevalence of poor MA among Malay patients, an effective
and efficient approach which could engage more patients within a shorter period of times to
improve the medication adherence problems is highly preferred (Odgers-Jewell 2017). Hence,
all the problem statements addressed above lead to the necessity of conducting this study,
which aims to investigate the effectiveness of the SGBI "KYM-TIFH" in improving MA among
Malay patients with T2DM.
Based on the problems stated above, this study aims (1) to measure the effectiveness of
MEDIHEALTH in improving the medication adherence level and the component of the extended TPB,
(2) to identify the component of the extended TPB that predicts medication adherence after
participating in MEDIHEALTH, and (3) to investigate the sustainability of the program.
Based on the first specific objective, ten hypotheses are to be tested:
H1a: Increase in intention to adhere would be mediated by improvements in attitude towards
adherence after baseline, which is achieved by participating in MEDIHEALTH.
H1b: Increase in intention to adhere would be mediated by improvements in subjective norm
towards adherence after baseline, which is achieved by participating in MEDIHEALTH.
H1c: Increase in medication adherence would be mediated by improvements in intention to
adhere after baseline, which is achieved by participating in MEDIHEALTH.
H1d: Increase in intention to adhere would be mediated by improvements in perceived
behavioural control towards adherence after baseline, which is achieved by participating in
MEDIHEALTH.
H1e: Increase in intention to adhere would be mediated by improvements in adherence
information after baseline, which is achieved by participating in MEDIHEALTH.
H1f: Before the intervention, there are no significant differences of medication adherence
level and the psychosocial variables related to it among the participants between the
intervention group and the control group.
H1g: After 3, 6 and 12 months of the program, the medication adherence levels among the
participants in the intervention group are significantly greater than the medication
adherence levels before the intervention.
H1h: After 3, 6 and 12 months of the program, the medication adherence levels among the
participants in the intervention group are significantly greater than the medication
adherence levels of the participants in the control group.
H1i: After 3, 6 and 12 months of the program, the HbA1c levels among the participants in the
intervention group are significantly greater than the HbA1c before the intervention.
H1j: After 3, 6 and 12 months of the program, the HbA1c levels among the participants in the
intervention group are significantly greater than the HbA1c levels of the participants in the
control group.
For the second specific objective, eight hypotheses are to be tested:
H2a: Improvement in attitude towards adherence will contribute to the increase in intention
to adhere.
H2b: Improvement in subjective norm towards adherence will contribute to the increase in
intention to adhere.
H2c: Improvement in perceived behavioural control towards adherence will contribute to the
increase in intention to adhere.
H2d: Improvement in perceived behavioural control towards adherence will contribute to the
increase in medication adherence.
H2e: Improvement in intention to adhere will contribute to the increase in medication
adherence.
H2f: Improvement in adherence information will contribute to the increase in perceived
behavioural control towards adherence.
H2g: Improvement in adherence information will contribute to the increase in medication
adherence.
H2i: Improvement in medication adherence level will contribute to the decrease in HbA1c
level.
Operational definitions:
1. Medication adherence: Medication adherence is defined as the level of patients in
complying with the medications prescribed by healthcare providers. Such level of
compliance is measured through 13 items self-efficacy for appropriate medication use
scale (Risser et al., 2007) which had been validated among chronic patients with low
literacy.
2. T2DM Malay patients: Type 2 Diabetes Mellitus Malay patients of this study refers to all
the patients who are prescribed with oral anti-hyperglycaemic agents (OHA) and obtain
their medications supply from the pharmacy department of Kota Samarahan Health Clinic
(KS-HC) and Petra Jaya Health Clinic (PJ-HC) during the study period. Such T2DM patients
whose identity card show their religion as Islam, will be considered as Malay T2DM
patients for this study.
3. Structured group based intervention: The structured group based intervention of this
study refers to the program "Know Your Medicine - Take it for Health" which was
formulated and employed by the Pharmaceutical Services Division of Sarawak State Health
Department in late 2016 under the national campaign "Know Your Medicine" to promote
medication adherence among T2DM Malay patients. The official name of the intervention is
"Kenali Ubat Anda - Ambillah untuk Kesihatan" in Malay language or "Know Your Medicine -
Take it for Health" in English with abbreviation KYM-TIFH.
4. Effectiveness: The effectiveness of this study refers to the improvement of HbA1c and
medication adherence level among T2DM Malay patients before and after the SGBI with such
improvement having a significant difference as compared to the results in control group.
Furthermore, the effectiveness of the SGBI will be complemented by the qualitative data
through focus group discussion and a semi-structured interview.
5. Complications: The complications in this study refers to the diabetes-related
complications including retinopathy, nephropathy, diabetic foot problems, ischemic heart
disease and stroke that had been diagnosed by doctors and were documented in patients'
medical records during the period of study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|